Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: The MaxCmin1 trial

Journal of Infectious Diseases

Volumn 188, Issue 5, 2003, Pages 635-642

  Dragsted, Ulrik Bak ^a   Gerstoft, Jan ^b   Pedersen, Court ^c   Peters, Barry ^e   Duran, Adriana ^h   Obel, Niels ^d   Castagna, Antonella ^l   Cahn, Pedro ⁱ   Clumeck, Nathan ^m   Bruun, Johan N ⁿ   Benetucci, Jorge ^j   Hill, Andrew ^f   Cassetti, Isabel ^k   Vernazza, Pietro ^o   Youle, Mike ^g   Fox, Zoe ^a   Lundgren, Jens D ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e ST THOMAS HOSPITAL   (United Kingdom)

^f ROCHE PRODUCTS LTD   (United Kingdom)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h HOSPITAL RAMOS MEJÍA   (Argentina)

ⁱ FUNDACIÓN HUÉSPED   (Argentina)

^j F J Muniz (FUNDAI)   (Argentina)

^k Helios Salud ^*  (Argentina)

^l SAN RAFFAELE HOSPITAL   (Italy)

^m SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

ⁿ ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^o CANTONAL HOSPITAL ST GALLEN   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CHOLESTEROL; INDINAVIR; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HAIR DISEASE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; KIDNEY DYSFUNCTION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0141612910     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/377288     Document Type: Article

References (21)

1. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-8.
2. Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000; 160:1123-32.
3. Flandre P, Raffi F, Descamps D, et al. Final analysis of the Trilege induction-maintenance trial: results at 18 months. AIDS 2002; 16:561-8.
4. D'Arminio MA, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14:499-507.
5. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000; 283:229-34.
6. Burger DM, Hoetelmans RM, Hugen PW, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther 1998; 3:215-20.
7. Phillips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS 2001; 15:2379-84.
8. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 25:221-8.
9. Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15:1517-26.
10. Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15:1089-95.
11. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2:105-13.
12. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38:41-57.
13. Buss N, Snell P, Bock J, Hsu A, Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 2001; 52:255-64.
14. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the HERS study. J Acquir Immune Defic Syndr 2001; 28:124-31.
15. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15:1369-77.
16. van Heeswijk RP, Veldkamp AI, Hoetelmans RM, et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999; 13:F95-9.
17. Arnaiz JA, Mallolas J, Podzamczer D, et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected subjects with suppressed viral load. AIDS 2003; 11:831-40.
18. Kirk O, Gerstoft J, Pedersen C, et al. Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort. HIV Med 2001; 2:43-51.
19. Veldkamp AI, van Heeswijk RP, Mulder JW, et al. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J Acquir Immune Defic Syndr 2001; 27:344-9.
20. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-46.
21. Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products. CPMP Working Party on Efficacy of Medicinal Products Note for Guidance III/3630/92-EN. Star Med 1995; 14:1659-82.